ACIU · AC Immune SA · Insider Trading
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-06-11 | AGUIAR-LUCANDER RENEE |
Director |
Award↑
Filing footnotes — Common Share (Direct)
On June 11, 2026, the Reporting Person received a restricted share unit grant of 16,568 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP). Comprised of 51,136 common shares underlying outstanding restricted share units. |
Common Share
|
16,568 |
| 2026-06-11 | Zuegel Martin |
Director |
Award↑
Filing footnotes — Common Share (Direct)
On June 11, 2026, the Reporting Person received a restricted share unit grant of 33,136 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP). Comprised of 71,408 common shares underlying outstanding restricted share units. |
Common Share
|
33,136 |
| 2026-06-11 | Zuegel Martin |
Director |
Award↑
Filing footnotes — Share Option (right to buy) (Direct)
On June 11, 2026, the Reporting Person received share options with respect to 77,778 shares under the SOIP. The share options will fully vest on June 10, 2027. |
Share Option (right to buy)
|
77,778 |
| 2026-06-11 | June Carl Howard |
Director |
Award↑
Filing footnotes — Share Option (right to buy) (Direct)
On June 11, 2026, the Reporting Person received share options with respect to 38,889 shares under the SOIP. The share options will fully vest on June 10, 2027. |
Share Option (right to buy)
|
38,889 |
| 2026-06-11 | Twyman Roy Ervin |
Director |
Award↑
Filing footnotes — Common Share (Direct)
On June 11, 2026, the Reporting Person received a restricted share unit grant of 16,568 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP). Includes 66,556 common shares underlying outstanding restricted share units. |
Common Share
|
16,568 |
| 2026-06-11 | June Carl Howard |
Director |
Award↑
Filing footnotes — Common Share (Direct)
On June 11, 2026, the Reporting Person received a restricted share unit grant of 16,568 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP). Includes 66,556 common shares underlying outstanding restricted share units. |
Common Share
|
16,568 |
| 2026-06-11 | Twyman Roy Ervin |
Director |
Award↑
Filing footnotes — Share Option (right to buy) (Direct)
On June 11, 2026, the Reporting Person received share options with respect to 38,889 shares under the SOIP. The share options will fully vest on June 10, 2027. |
Share Option (right to buy)
|
38,889 |
| 2026-06-11 | AGUIAR-LUCANDER RENEE |
Director |
Award↑
Filing footnotes — Share Option (right to buy) (Direct)
On June 11, 2026, the Reporting Person received share options with respect to 38,889 shares under the SOIP. The share options will fully vest on June 10, 2027. |
Share Option (right to buy)
|
38,889 |
| 2026-06-11 | Buetler Monika |
Director |
Award↑
Filing footnotes — Share Option (right to buy) (Direct)
On June 11, 2026, the Reporting Person received share options with respect to 41,667 shares under the SOIP. The share options will fully vest on June 10, 2027. |
Share Option (right to buy)
|
41,667 |
| 2026-06-11 | Buetler Monika |
Director |
Award↑
Filing footnotes — Common Share (Direct)
On June 11, 2026, the Reporting Person received a restricted share unit grant of 17,751 units under the AC Immune SA 2016 Stock Option and Incentive Plan (SOIP). Includes 70,656 common shares underlying outstanding restricted share units. |
Common Share
|
17,751 |
| 2026-05-15 | Pfeifer Andrea |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Common Share (Direct)
The price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.825. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Includes 1,921,005 common shares underlying outstanding restricted share units. |
Common Share
|
10,000 |
| 2026-04-15 | Pfeifer Andrea |
Director, Chief Executive Officer |
Sell↓
Filing footnotes — Share (Direct)
This Form 4/A amends the Form 4 filed on April 16, 2026, inadvertently reporting in column 3 a purchase of 10,000 shares on behalf of the reporting person. This amendment corrects that filing to reflect that the reporting person sold 10,000 shares. The price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.05 to $3.19, inclusive. Includes 1,921,005 common shares underlying outstanding restricted share units. |
Share
|
10,000 |